Amgen has announced an additional $300 million investment to expand its manufacturing operations in Puerto Rico, increasing its overall commitment to U.S.-based projects to nearly $2 billion over the past year. The new funding will support ongoing upgrades at the company’s Juncos facility, a site that has been in operation since 1992 and plays a central role in Amgen’s global production network, supplying medicines to more than 60 countries.
The latest investment builds on plans disclosed in late September, when the company outlined a $650 million initiative to enhance biologics manufacturing capacity at the same location. At that time, Amgen also said the project would result in the creation of hundreds of new jobs. The Juncos campus, which as of 2022 included more than 20 buildings and employed thousands of workers, remains one of the company’s largest and most established production hubs.
According to the company, the additional $300 million does not alter the scope or hiring expectations previously announced. Instead, it extends the scale of the expansion while maintaining the same strategic direction. The company stated that the project will reinforce existing advanced manufacturing roles, contribute to workforce development in Puerto Rico, and generate hundreds of construction jobs during the buildout phase.
The investment comes at a time when pharmaceutical companies are increasing domestic spending amid evolving U.S. trade and pricing policies. Industry activity has been influenced in part by proposed tariff measures and related agreements with the U.S. government. Amgen is among 17 large drugmakers that have entered into “most favored nation” pricing arrangements with the White House. These agreements provide temporary exemptions from certain pharmaceutical tariffs introduced under policies announced earlier this year.
In early April, the U.S. administration said it would apply tariffs of up to 100% on some patented medicines imported into the country, while allowing exemptions through specific trade agreements and negotiated industry terms. These developments have contributed to a broader wave of investment announcements across the sector, as companies respond to evolving tariff and pricing policies.
Commenting on the Puerto Rico expansion, Amgen CEO Robert Bradway said, “Amgen has been a leader in U.S. biomanufacturing for decades, and this expansion reflects our continued commitment to American manufacturing.” He added that expanding operations in Puerto Rico is intended to help ensure patient access to medicines, support domestic supply chains, and contribute to job creation.
Beyond Puerto Rico, Amgen has outlined additional U.S.-based projects over the past year. These include plans for a $900 million expansion of a biomanufacturing facility in central Ohio, as well as the construction of a $600 million research and development center in Thousand Oaks, California. The California site, located near the company’s headquarters, is expected to accommodate researchers and support efforts in next-generation drug discovery, while also creating hundreds of new jobs.
Meanwhile, other pharmaceutical companies are advancing their own U.S. expansion strategies. Novartis recently announced plans for a new active pharmaceutical ingredient facility in Morrisville, North Carolina. This project represents the seventh and final site in the company’s broader $23 billion U.S. investment program, which also includes multiple manufacturing and radioligand therapy facilities across several states.
Amgen continues to scale its global manufacturing capabilities, with Amgen announcing an additional $300 million investment in Puerto Rico. This move brings Amgen’s total U.S. investment commitments in the region close to $2 billion, reinforcing Amgen’s long-term strategy of expanding production capacity and strengthening supply chain resilience.
Amgen’s Expansion Strategy in Puerto Rico
Amgen has maintained a strong presence in Puerto Rico for decades, and this latest investment underscores Amgen’s confidence in the region as a critical hub for biopharmaceutical manufacturing. The new funding will support infrastructure upgrades, advanced production technologies, and workforce development.
By expanding operations in Puerto Rico, Amgen aims to enhance its ability to meet growing global demand for biologic medicines while maintaining high-quality manufacturing standards.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
